DE69625516T2 - Verwendung von il-10 zur wundheilung mit verminderter narbenbildung - Google Patents

Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Info

Publication number
DE69625516T2
DE69625516T2 DE69625516T DE69625516T DE69625516T2 DE 69625516 T2 DE69625516 T2 DE 69625516T2 DE 69625516 T DE69625516 T DE 69625516T DE 69625516 T DE69625516 T DE 69625516T DE 69625516 T2 DE69625516 T2 DE 69625516T2
Authority
DE
Germany
Prior art keywords
wounds
modified form
partially modified
healing
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69625516T
Other languages
German (de)
English (en)
Other versions
DE69625516D1 (de
Inventor
William Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DE69625516D1 publication Critical patent/DE69625516D1/de
Publication of DE69625516T2 publication Critical patent/DE69625516T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Eye Examination Apparatus (AREA)
  • Prostheses (AREA)
DE69625516T 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung Expired - Lifetime DE69625516T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines
PCT/GB1996/001930 WO1997005894A1 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10

Publications (2)

Publication Number Publication Date
DE69625516D1 DE69625516D1 (de) 2003-01-30
DE69625516T2 true DE69625516T2 (de) 2003-09-25

Family

ID=10778967

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625516T Expired - Lifetime DE69625516T2 (de) 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung

Country Status (13)

Country Link
US (2) US6387364B1 (enExample)
EP (1) EP0871473B1 (enExample)
JP (1) JP4050317B2 (enExample)
AT (1) ATE229814T1 (enExample)
AU (1) AU719089B2 (enExample)
CA (1) CA2229078C (enExample)
DE (1) DE69625516T2 (enExample)
DK (1) DK0871473T3 (enExample)
ES (1) ES2187665T3 (enExample)
GB (1) GB2304047A (enExample)
PT (1) PT871473E (enExample)
WO (1) WO1997005894A1 (enExample)
ZA (1) ZA966744B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0941108T3 (da) * 1996-12-04 2002-11-18 Renovo Ltd Sårheling og behandling af fibrose
AU6045198A (en) * 1997-02-05 1998-08-25 Schering Corporation Use of il-4 and/or il-10 to treat proliferative glomerulonephritis
AU6951300A (en) * 1999-09-08 2001-04-10 Schering Corporation Novel uses of mammalian ccr6 receptors and related reagents
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
WO2003062373A2 (en) * 2001-10-18 2003-07-31 The Children's Hospital Of Philadelphia Methods and materials for the recruitment of endothelial cells
JP4790609B2 (ja) * 2003-07-15 2011-10-12 バーイラン ユニバーシティー 創傷治癒のための方法及び薬剤組成物
ES2375565T3 (es) 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
GB0500643D0 (en) * 2005-01-13 2005-02-23 Renovo Ltd Medicaments
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
KR20100040912A (ko) * 2007-07-30 2010-04-21 힐로 리미티드 약제학적 조성물 및 관련 방법
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2008343840A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
WO2009120799A2 (en) * 2008-03-25 2009-10-01 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
ES2957546T3 (es) 2008-12-17 2024-01-22 Merck Sharp & Dohme Producción de mono- y di-PEG-IL10; y usos
NZ600583A (en) * 2009-02-24 2013-08-30 Healor Ltd Visfatin therapeutic agents for the treatment of acne and other conditions
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
EP2691515A2 (en) * 2011-03-31 2014-02-05 President and Fellows of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
NZ701949A (en) * 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10098929B2 (en) 2013-08-02 2018-10-16 Children's Hospital Medical Center Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
EP0280560B1 (en) 1987-02-27 1994-05-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Membrane structure coated with low pI protein and methods of making and using
JPH0611706B2 (ja) * 1989-01-20 1994-02-16 ザ ユニバーシティ オブ メルボルン フィブリン溶解
US5242902A (en) 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
WO1991007186A1 (en) * 1989-11-21 1991-05-30 The University Of Melbourne Anti-inflammatory compositions and methods
ES2124702T3 (es) 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
JPH0747545B2 (ja) * 1991-01-10 1995-05-24 シェリング・コーポレーション 創傷治癒及び修復の修復段階を促進し、かつ感染した創傷及び糖尿病哺乳類の創傷の治癒を促進するためのｉｌ−４の用途
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
WO1993004164A1 (en) 1991-08-26 1993-03-04 THE STATE OF OREGON acting by and through THE STATE OF BOARD OF HIGHER EDUCATION on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY Keratinocyte-derived conditioned medium as a source of growth factors
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
AU7043694A (en) * 1993-05-27 1994-12-20 Regents Of The University Of Michigan, The Method of treatment and prevention of immune complex-induced lung injury
IL110413A0 (en) 1993-07-26 1994-10-21 Schering Corp Agonists and antagonists of human interleukin-10
EP0968723B1 (en) * 1994-03-29 2009-07-01 Renovo Limited Healing of wounds or fibrotic disorders using at least one agent against a growth factor
CA2205572A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
GB9516012D0 (en) 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2304045A (en) 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases

Also Published As

Publication number Publication date
AU719089B2 (en) 2000-05-04
CA2229078C (en) 2010-04-20
US7052684B2 (en) 2006-05-30
EP0871473A1 (en) 1998-10-21
US20020128447A1 (en) 2002-09-12
AU6666096A (en) 1997-03-05
PT871473E (pt) 2003-03-31
CA2229078A1 (en) 1997-02-20
GB2304047A (en) 1997-03-12
ZA966744B (en) 1998-02-09
EP0871473B1 (en) 2002-12-18
DK0871473T3 (da) 2003-04-14
JP4050317B2 (ja) 2008-02-20
US6387364B1 (en) 2002-05-14
JPH11510505A (ja) 1999-09-14
ATE229814T1 (de) 2003-01-15
GB9516287D0 (en) 1995-10-11
WO1997005894A1 (en) 1997-02-20
DE69625516D1 (de) 2003-01-30
ES2187665T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
US7052684B2 (en) Methods of healing wounds and fibrotic disorders using IL-10
DE3782358T2 (de) Wundheilende zusammensetzung.
DE68924069T2 (de) Kollagen-wundheilmatrizen und verfahren zur herstellung.
DE69002795T2 (de) Stabilisierte, den epidermalen Wachstumsfaktor enthaltende Mittel.
EP1526867B1 (de) Erythropoietin in subpolycythämischen dosen
DE69830582T2 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE69231486T2 (de) Zusammensetzung enthaltend pdgf und dexamethason zur förderung von gewebsreparatur und -regenerierung
DE69228949T2 (de) Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE60130008T2 (de) Proteinkombinationen zur heilung von wunden
DE69119879T2 (de) Epitheliocytenwachstumsbeschleuniger
EP0203580B1 (de) Gamma-IFN als Wirkstoff zur Hemmung (Verhinderung) von Abbauprozessen im Knochen
DE69033703T2 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
DE69031218T2 (de) Wundheilung
DE3781250T2 (de) Verwendung vom "cartilage-inducing faktor b(cif-b)" zur herstellung eines arzneimittels gegen das wachstum von tumoren.
DE69633396T2 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
DE69009748T2 (de) Fgf enthaltende stabilisierte zubereitungen.
DE3853721T2 (de) Verwendungen von rekombinantem koloniestimulierendem faktor-1.
DE69716460T2 (de) Wundheilung und behandlung von fibrose
DE69626987T2 (de) Pharmaceutische komposition
DE69211723T2 (de) Mit einem Zellwachstumsfaktor bewirkte Anregung von Wachstum im Knocheninneren
DE69819563T2 (de) Topische zusammensetzung enthaltend menschlichen epidermalen wachstumsfaktor
EP0493662B1 (de) Verwendung von Superoxiddismutasen für die Herstellung von Arzneimitteln zur Prophylaxe und/oder Behandlung von Organversagen bei Risikopatienten mit Polytrauma als Unfallfolge
DE69626050T2 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
DE60116982T2 (de) Verwendung einer Stutenmilchfraktion ausgewählt aus Magermilch, Molke und Natriumcaseinat mit entzündungshemmender Wirkung
AT403434B (de) Topische zusammensetzung zur beschleunigung der wundheilung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition